# INTERPACE BIOSCIENCES, INC. (IDXG) · Edgar & Edgarette company card

> Interpace Biosciences (IDXG) saw revenue fall 17.5% in FY2025 to $39 million, operating margin 10.5% against a 1.2% median for surgical & medical instruments & apparatus, equity 66.1% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1054102 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/IDXG) · [JSON](https://www.pops4.com/boards/company/IDXG.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $39M |
| Revenue growth, 1 year | -17.5% |
| Revenue growth per year | 4.0% |
| Operating margin | 10.5% (prior year 17.3%) |
| Net margin | 63.5% |
| Operating cash flow | $6M |
| Capital spending | $356,000 |
| Free cash flow | $5M |
| Cash | $3M |
| Long-term debt | — |
| Total assets | $34M |
| Total equity | $22M |
| Equity ÷ assets | 66.1% |
| Return on equity | 109.9% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -16.52 (distress zone)
- Piotroski F: 5 of 9 (middling)
- Beneish M: 1.99 (above the −1.78 line)
- Health Harbor boat: Sound ship · one warning sign · revenue is hard to predict: its 80% range is ±43%
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $38.7M (FY2025). Experience: revenue down 17.5% on the year, up 4.0% a year over 4 years; operating margin 10.5%, down from 17.3%. Soundness: equity 66.1% of assets, return on equity 109.9%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $22.8M and $56.6M next year (method v4.1: its own 6-year record of growth weighed at 63% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $21.4M to $60.4M. A statistical range, not company guidance. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin 10.5% against a 1.2% median; growth -17.5% against 11.6%.

Range logged 2026-09-28, receipt c14bdb869b9690d6, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

No warning filings in the window.

## Recent filings

- 8-K · filed 2026-10-15 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1054102/000149315226047090/0001493152-26-047090-index.htm)
- S-1 · filed 2026-09-25 · [filing](https://www.sec.gov/Archives/edgar/data/1054102/000149315226044208/0001493152-26-044208-index.htm)
- 8-K · filed 2026-08-27 · 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1054102/000149315226040329/0001493152-26-040329-index.htm)
- 8-K · filed 2026-08-21 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/1054102/000149315226039530/0001493152-26-039530-index.htm)
- 8-K · filed 2026-08-12 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1054102/000149315226037360/0001493152-26-037360-index.htm)
- 10-Q · filed 2026-08-10 · [filing](https://www.sec.gov/Archives/edgar/data/1054102/000149315226036895/0001493152-26-036895-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001054102.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1054102

## Cite

POPS4, Edgar & Edgarette: INTERPACE BIOSCIENCES, INC. (IDXG) company card, from the company's own SEC filings, accessed 2026-11-12, https://www.pops4.com/boards/company/IDXG. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.